Sarepta Therapeutics, Inc.

Apr 08 10:00pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ) by TipRanks Apr 04 7:46pm ET Buy Rating on Sarepta Therapeutics Amidst Anticipated Drug Approval and Market Potential by TipRanks Mar 22 7:56am ET Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT) by TipRanks Mar 13 5:45am ET Sarepta Therapeutics: A Strong Buy on Promising Drug Outlook and Strategic Growth Potential by TipRanks Mar 13 2:35am ET Buy Rating for Sarepta Therapeutics Amidst Promising Developments and Strategic Partnerships by TipRanks Mar 07 8:17am ET PepGen price target lowered to $20 from $21 at Wedbush by TipRanks Mar 06 7:26am ET Sarepta Therapeutics’ Elevidys Poised for Market Leadership in DMD, Despite Emerging Competitors by TipRanks Mar 06 6:31am ET Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy bio (TSVT) by TipRanks Mar 01 7:48am ET Sarepta Therapeutics (SRPT) Gets a Hold from Oppenheimer by TipRanks Mar 01 7:19am ET Sarepta price target raised to $167 from $164 at UBS by TipRanks Mar 01 1:31am ET Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Alcon (ALC) and Sarepta Therapeutics (SRPT) by TipRanks Mar 01 1:12am ET Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Clinical Advancements by TipRanks Mar 01 12:55am ET Buy Rating Affirmed for Sarepta Therapeutics as Elevidys Shows Strong Sales and Promising Outlook by TipRanks Feb 29 8:29am ET Sarepta price target raised to $157 from $151 at RBC Capital by TipRanks Feb 29 7:31am ET Analysts Are Bullish on These Healthcare Stocks: Addus Homecare (ADUS), Jazz Pharmaceuticals (JAZZ) by TipRanks Feb 29 7:25am ET Sarepta Therapeutics: A Strong Buy on Robust Financials and Elevidys’ Market Success by TipRanks Feb 29 6:55am ET Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Drug Pipeline Prospects by TipRanks Feb 29 6:18am ET Sarepta price target raised to $172 from $160 at Citi by TipRanks Feb 29 6:12am ET Sarepta price target raised to $185 from $141 at Barclays by TipRanks Feb 29 5:50am ET Analysts’ Top Healthcare Picks: Amgen (AMGN), Sarepta Therapeutics (SRPT) by TipRanks Feb 29 5:30am ET Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX), Sarepta Therapeutics (SRPT) and AptarGroup (ATR) by TipRanks Feb 28 10:10pm ET Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Immunocore Holdings (IMCR) by TipRanks Feb 28 4:29pm ET Sarepta reports Q4 EPS 82c, consensus 1c by TipRanks Feb 20 7:40am ET Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT) by TipRanks Feb 20 7:15am ET Sarepta price target raised to $165 from $135 at TD Cowen by TipRanks Feb 20 7:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF) and Sarepta Therapeutics (SRPT) by TipRanks Feb 19 6:35pm ET Sarepta Therapeutics’ Stock Buy Rating Affirmed Amid Positive FDA Regulatory Milestones by TipRanks Feb 16 5:45pm ET Buy Rating on Sarepta Therapeutics Amid Favorable FDA Review and Potential Broadening of Elevidys’ Label by TipRanks Feb 16 5:36pm ET Buy Rating Affirmed for Sarepta Therapeutics Amid Anticipated Elevidys Label Expansion and Market Growth Potential by TipRanks Feb 16 5:35pm ET Sarepta Therapeutics: Strong Buy on Regulatory Tailwinds and Expanding Market Potential for Elevidys by TipRanks Feb 16 5:20pm ET Sarepta price target raised to $169 from $164 at BofA by TipRanks